Edwards Lifesciences
1,330 hedge funds and large institutions have $47.1B invested in Edwards Lifesciences in 2026 Q2 according to their latest regulatory filings, with 164 funds opening new positions, 467 increasing their positions, 467 reducing their positions, and 102 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
61% more first-time investments, than exits
New positions opened: 164 | Existing positions closed: 102
17% more capital invested
Capital invested by funds: $40.4B → $47.1B (+$6.75B)
3.23% more ownership
Funds ownership: 87.49% → 90.73% (+3.2%)
3% more funds holding
Funds holding: 1,290 → 1,330 (+40)
0% more repeat investments, than reductions
Existing positions increased: 467 | Existing positions reduced: 467
6% less call options, than puts
Call options by funds: $168M | Put options by funds: $180M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aristotle Capital Management
Los Angeles,
California
|
+$726M |
| 2 |
BlackRock
New York
|
+$519M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$435M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$317M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$291M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$1.07B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$508M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$434M |
| 4 |
Bank of New York Mellon
New York
|
-$222M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$138M |
EW Hedge Fund Activity: Q2 2026 in Review
1,330 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2026, worth a combined $47.1B — up 17% from $40.4B a quarter earlier.
Buyers outnumbered sellers: 164 funds opened new EW positions and 102 closed out — a net gain of 62 holders — while 467 added to existing stakes and 467 trimmed.
The largest buyer was Aristotle Capital Management, opening a new position worth an estimated $726M. The largest seller was Jennison Associates, cutting an estimated $1.07B.
- 1,330 institutional investors held Edwards Lifesciences (EW) as of Q2 2026, up from 1,290 in Q1 2026.
- Funds reported $47.1B of Edwards Lifesciences stock for Q2 2026, up 17% quarter-over-quarter.
- 164 funds opened new Edwards Lifesciences positions in Q2 2026 and 102 closed out, a net change of +62 holders.
- The largest Edwards Lifesciences buyer in Q2 2026 was Aristotle Capital Management, an estimated $726M added.
- The largest Edwards Lifesciences seller in Q2 2026 was Jennison Associates, an estimated $1.07B sold.
Based on aggregated 13F filings for Q2 2026.